On Friday, H.C. Wainwright adjusted its outlook on shares of Prothena Corp (NASDAQ:PRTA), reducing the price target to $48 from the previous $84, while maintaining a Buy rating on the stock. Currently trading at $16.01, PRTA sits well below its 52-week high of $41.55, with analyst targets ranging from $22 to $94.
According to InvestingPro data, the stock currently appears fairly valued based on its proprietary Fair Value model. This revision follows the recent disclosure of Phase 2b PADOVA study results by Roche, which indicated that the study narrowly missed the statistical significance in its primary endpoint of time to confirmed motor progression.
The analyst noted that the full data set has not been released, but it would be important to compare the performance of the placebo arm with the active group. The PADOVA study, which tested the motor function impact of prasinezumab, enrolled 586 individuals with early-stage Parkinson's disease (PD).
It was highlighted that 74.4% of participants were on stable L-DOPA and 25.6% on MAO-Bi therapy at baseline. With a market capitalization of $861.5 million and an overall Financial Health score rated as 'FAIR' by InvestingPro, the company maintains a strong current ratio of 11.52, indicating robust short-term liquidity.
The trial aimed to measure the time to a confirmed motor progression event, defined as an increase of at least 5 points in the UPDRS Part III score in the off state at 18 months. The study's broad inclusion criteria and the fact that participants had a higher Hoehn and Yahr stage and longer time since diagnosis compared to those in the PASADENA trial were significant factors considered in the analysis.
Encouraging results were observed in a pre-specified analysis of the population treated with levodopa, which accounted for 75% of the participants. This subset showed a hazard ratio of 0.79 [0.63-0.99] with a nominal p-value of 0.0431, suggesting a consistent data pattern.
In light of the available data and the uncertainty surrounding the next steps for the Prasi program, H.C. Wainwright has re-evaluated the Probability of Success (PoS) and overall market penetration assumptions for the program, leading to the new price target of $48.
Despite the reduction, the firm reiterates its Buy rating on Prothena Corp shares. The stock has experienced significant volatility, with a YTD return of -56%, though it has shown recent momentum with a 25% gain in the past week.
For deeper insights into PRTA's valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which includes detailed analysis of the company's financial health and market position.
In other recent news, Prothena Corporation has seen its share price target revised, following an unsuccessful Phase 2b PADOVA study for Parkinson's disease. Oppenheimer adjusted the price target from $62 to $58, while maintaining an Outperform rating.
The company's financial health is rated as "FAIR" by InvestingPro, with a strong balance sheet and minimal debt-to-equity ratio. Despite the setback with the PADOVA study, attention shifts to the upcoming AFFIRM-AL study, anticipated to be a significant event for Prothena in the first half of 2025.
The company has outlined a potential $1 billion commercial opportunity for its birtamimab treatment, which could serve approximately 4,000 patients in the United States. Analyst firms, including H.C. Wainwright and BofA Securities, have adjusted their price targets and ratings for Prothena.
The company's second-quarter financial results for 2024 reported operating expenses of $73.6 million and a cash balance of $564 million. Prothena's full-year 2024 guidance anticipates a net loss in the range of $120 million to $135 million, largely due to an $80 million payment from Bristol Myers (NYSE:BMY) Squibb for global rights to PRX019. These are the recent developments for Prothena Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.